Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

Biotech N E W S AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has been dosed in Agenus (AGEN) Phase 1 clinical trial of its checkpoint inhibitor product AGEN1884. The open-label, multicenter trial in patients...

April 27, 2016

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid to acquire Medivation for $9.3 billion (£6.37B ). Sanofi is expected to pay $52.50 per share in cash for Medivation. Why Medivation? Sanofi's chief executive...

April 28, 2016

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

By June, which is next month, Incyte (INCY) will be the owner of the European operations of Ariad (ARIA) . That’s what both firms have announced yesterday. Among other details, the firms decided on signing a licensing agreement for exclusive...

May 10, 2016

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent rights to Sovaldi hepatitis C treatment. More than a victory for Gilead, it was the prevalence of fairness after years of underestimating the power...

May 11, 2016

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief Executive Pascal Soriot said that while DNA damage response was under-recognized by investors, oncologists were already “very excited” by its potential of the drugs...

May 16, 2016

Portola: Solving the Huge Problem of the New Anticoagulants

Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have thrombotic incidents (clots) in patients taking anticoagulants (blood thinners) and bleeding remained the most feared side effect of these indispensable life-saving drugs. In recent...

May 18, 2016

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance to treatment, metastasis, recurrence, etc. Today we have several news, including one that might have cleared a puzzle regarding a continuous growth of colon...

May 19, 2016

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 program for Theravance Biopharma’s ( TBPH ) revefenacin (TD-4208) . The drug is an investigational long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease...

June 3, 2016

At ASCO: Exelixis Has Great News for Cobimetyx on RCC

Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for patients with Advanced RCC AT the ASCO Meeting: ABSTRACT #4557, #4558 Cabometyx’™ benefit was robust and consistent regardless of prior treatment, location and extent...

June 6, 2016

Great News for Celator That Might Be Great News for Jazz Pharmaceuticals

CELATOR PHARMACEUTICALS Good News That Might Go to JAZZ Pharmaceuticals Celator Pharmaceuticals ( CPXX ) : At the European Hematology Association (EHA) 21st Annual Congress, Celator presented positive response rate results in acute myeloid leukemia ( AML) patients with the...

June 16, 2016

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024